Drug screening model meets cancer organoid technology
Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived x...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451679/ https://www.ncbi.nlm.nih.gov/pubmed/32822897 http://dx.doi.org/10.1016/j.tranon.2020.100840 |
_version_ | 1783575027286802432 |
---|---|
author | Liu, Chen Qin, Tianyu Huang, Yuhan Li, Yuan Chen, Gang Sun, Chaoyang |
author_facet | Liu, Chen Qin, Tianyu Huang, Yuhan Li, Yuan Chen, Gang Sun, Chaoyang |
author_sort | Liu, Chen |
collection | PubMed |
description | Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening. |
format | Online Article Text |
id | pubmed-7451679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-74516792020-09-09 Drug screening model meets cancer organoid technology Liu, Chen Qin, Tianyu Huang, Yuhan Li, Yuan Chen, Gang Sun, Chaoyang Transl Oncol Review article Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-specific tumor evolution in patient-derived xenograft (PDX). So, cancer organoid has been widely applied to preclinical drug evaluation, biomarker identification, biological research, and individualized therapy. Besides, cancer organoid can be preserved, resuscitated, passed infinitely, and mechanically cultured on a chip for drug screening; it has become one of the partial models for low/high-throughput drug screening in the preclinical trial in vitro. Therefore, this review presents the recent developments of tumor organoids for drug screening, which will introduce from four aspects, including the stability/credibility, types, application, deficiency and prospect of the tumor organoids model for drug screening. Neoplasia Press 2020-08-18 /pmc/articles/PMC7451679/ /pubmed/32822897 http://dx.doi.org/10.1016/j.tranon.2020.100840 Text en © 2020 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. CC BY-NC-ND 4.0. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review article Liu, Chen Qin, Tianyu Huang, Yuhan Li, Yuan Chen, Gang Sun, Chaoyang Drug screening model meets cancer organoid technology |
title | Drug screening model meets cancer organoid technology |
title_full | Drug screening model meets cancer organoid technology |
title_fullStr | Drug screening model meets cancer organoid technology |
title_full_unstemmed | Drug screening model meets cancer organoid technology |
title_short | Drug screening model meets cancer organoid technology |
title_sort | drug screening model meets cancer organoid technology |
topic | Review article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451679/ https://www.ncbi.nlm.nih.gov/pubmed/32822897 http://dx.doi.org/10.1016/j.tranon.2020.100840 |
work_keys_str_mv | AT liuchen drugscreeningmodelmeetscancerorganoidtechnology AT qintianyu drugscreeningmodelmeetscancerorganoidtechnology AT huangyuhan drugscreeningmodelmeetscancerorganoidtechnology AT liyuan drugscreeningmodelmeetscancerorganoidtechnology AT chengang drugscreeningmodelmeetscancerorganoidtechnology AT sunchaoyang drugscreeningmodelmeetscancerorganoidtechnology |